A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
about
Costs of Hospital Admission on Primary Immunodeficiency Diseases.T-cell Receptor and K-deleting Recombination Excision Circles in Newborn Screening of T- and B-cell Defects: Review of the Literature and Future Challenges.Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders.TREC Based Newborn Screening for Severe Combined Immunodeficiency Disease: A Systematic ReviewHistory and current status of newborn screening for severe combined immunodeficiency.The case for newborn screening for severe combined immunodeficiency and related disordersThe long quest for neonatal screening for severe combined immunodeficiency.MALDI-TOF-MS Assay to Detect the Hemizygous 22q11.2 Deletion in DNA from Dried Blood Spots.The Role of Information Provision in Economic Evaluations of Newborn Bloodspot Screening: A Systematic ReviewCost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington StateThe Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 yearsA public health economic assessment of hospitals' cost to screen newborns for critical congenital heart disease.Neonatal screening for severe combined immunodeficiencyNewborn screening for primary immunodeficiencies: beyond SCID and XLA.The case for mandatory newborn screening for severe combined immunodeficiency (SCID).Expanded newborn screening by mass spectrometry: New tests, future perspectives.Primary Immunodeficiency Diseases in Saudi Arabia: a Tertiary Care Hospital Experience over a Period of Three Years (2010-2013).Advances in neonatal screening for primary immune deficiencies.Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement.Genetics professionals' opinions of whole-genome sequencing in the newborn period.Immunodeficiencies Associated with Abnormal Newborn Screening for T Cell and B Cell Lymphopenia.Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network.Haematopoietic stem cell transplantation for severe combined immunodeficiency: Long-term health outcomes and patient perspectives.First Year of Israeli Newborn Screening for Severe Combined Immunodeficiency-Clinical Achievements and Insights.An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia.Severe combined immunodeficiency (SCID) in Canadian children: a national surveillance study.Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency.Fifty years of newborn screening.Newborn screening for SCID: three years of experience.A Novel Homozygous Mutation Leading to T-B+NK- SCID in Two Brazilian Patients
P2860
Q33575500-15DD826E-2E35-4FB5-A193-A8D9D3F8D133Q34074060-56268942-D219-4521-971E-1D8D28CEB6A1Q34866575-520D5883-EE04-4852-84CE-B61166009A28Q35609753-FD7BEF73-813D-42BE-973F-CD41A146ED5FQ35613205-3E93D01D-7626-4940-B507-0623AD894954Q35761004-147EA253-A0F3-4F21-B458-E8AD79BB152CQ35803435-CB393C9C-DE58-481C-A054-615A8B9FCDCBQ35846619-4AB8F929-708F-418D-BFD6-ABB68ED86252Q36573343-4FD49B5F-ACA6-4FC6-A651-63263CC9E87EQ36839938-3E5DFEBD-C6FC-4619-BFF0-AFCA4E20B75FQ37015264-30AA14A4-9D09-4CBB-A7B5-7F01B6524B72Q37137721-F7D98EF5-7D20-43E5-AD8A-B78EF3101E6AQ37391725-F57A1C81-5535-4F26-A472-32AA4D12E4FDQ37946150-0AD9409F-C995-4333-9A9C-349179757B8FQ37974987-3B1E96B8-8ABE-4FE5-9664-707269531CF1Q38201349-AF2F508F-2A23-4E0B-93C3-9082D1C73B64Q38465134-DBB37237-6CA3-467C-8148-DB072FB138F4Q38591227-CE7EDBA7-E7DD-48EF-BBF6-D14A1413083BQ38832208-A5E934FD-83C0-4873-BBC3-87A4D2ABAAFEQ38948860-03CF3B54-16F7-4E8D-B310-8F1385637A29Q39107529-B9A1DC73-EF74-4E6F-B816-B300C39CC511Q39206354-F1FA4321-028C-4FBA-8904-A83810914A1FQ40070985-F7FFF1BC-224A-4D42-B15E-450A53245839Q40209304-C0C7310D-7110-4A50-AD98-09D9A00BE6D4Q43878336-6EAD93A9-5FEA-4AF5-BCAA-26942FC193B1Q44830662-0EF6B94E-40F0-4555-8D24-DD4498272102Q45128775-6BD9E727-173F-47F1-9550-1D689A45CAA4Q46527875-635CE167-EA4B-4B92-B5D1-5FF9236B27E0Q48053257-2999721F-0739-47E3-8589-79011CB46D17Q51485505-B07B033F-711C-4CD6-A628-E9995B86E1E2Q58735482-B0FD2010-17D6-4434-B4A7-5A3D1C0E4119
P2860
A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
A Markov model to analyze cost ...... bined immunodeficiency (SCID).
@ast
A Markov model to analyze cost ...... bined immunodeficiency (SCID).
@en
type
label
A Markov model to analyze cost ...... bined immunodeficiency (SCID).
@ast
A Markov model to analyze cost ...... bined immunodeficiency (SCID).
@en
prefLabel
A Markov model to analyze cost ...... bined immunodeficiency (SCID).
@ast
A Markov model to analyze cost ...... bined immunodeficiency (SCID).
@en
P2093
P2860
P1476
A Markov model to analyze cost ...... bined immunodeficiency (SCID).
@en
P2093
Francisco A Bonilla
Jennifer M Puck
Joie Davis
Michael Apkon
Sung-Yun Pai
P2860
P304
P356
10.1016/J.YMGME.2011.07.007
P577
2011-07-12T00:00:00Z